VTI’s Interfuse is an interbody lumbar fusion system that allows for less invasive approaches to lumbar fusion operations due to smaller access channels and intra-operative assembly, the Minnetonka, Minn.-based company said.
“While our products have approval in 38 markets worldwide, China is a key market. We are excited that our technologies will be available to surgeons and patients in China,” VTI CEO Matt Kyle said in a press release.
The initial Chinese launch will take place in Hong Kong and Macau in the 4th quarter of this year, VTI said, and will follow to mainland China after the company receives regulatory approval.
“Orthopedic implants are a key area in our product portfolio and the Interfuse system offers unique benefits over other fusion products. ECM is pleased to be partnering with VTI to bring a next generation fusion implant to the China market,” ECM U.S. veep Brian Hakim, said in prepared remarks.